Pioneering Stem Cell/Gene Therapy Trials Contributor(s): Bertolotti, Roger (Author), Ozawa, Keiyo (Author), Kirk Hammond, H. (Author) |
|
ISBN: 9067643947 ISBN-13: 9789067643948 Publisher: CRC Press OUR PRICE: $275.50 Product Type: Hardcover - Other Formats Published: October 2003 Annotation: The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene therapy or emerging autologous stem cell transplantation. Highlights also include 1) promises of the breakthrough combination of stem cell- and transient gene-therapy, 2) gene therapy trials for neurodegenerative disease on non-human primates where long-term gene therapy might involve brain stem cells, and 3) the first clinical trial with non-invasive monitoring of therapeutic gene expression as a prospective conclusion. This volume will be of value and interest to researchers in this exciting field. |
Additional Information |
BISAC Categories: - Medical | Diseases - Architecture | Interior Design - General - Science | Life Sciences - Genetics & Genomics |
Dewey: 616.042 |
LCCN: 2004300806 |
Series: Progress in Gene Therapy |
Physical Information: 0.78" H x 6.36" W x 9.66" (1.70 lbs) 330 pages |
Descriptions, Reviews, Etc. |
Publisher Description: The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene therapy or emerging autologous stem cell transplantation. Highlights also include 1) promises of the breakthrough combination of stem cell- and transient gene-therapy, 2) gene therapy trials for neurodegenerative disease on non-human primates where long-term gene therapy might involve brain stem cells, and 3) the first clinical trial with non-invasive monitoring of therapeutic gene expression as a prospective conclusion. |